Co-administered internalizing RGD peptide enhanced anti-PD-L1 therapy in HCC by improving antibody tumor penetration, increasing T cell infiltration, and overcoming the immunosuppressive microenvironment.
Peptide unlocks immunotherapyA simple co-administered RGD peptide enabled anti-PD-L1 antibody to penetrate liver tumors, overcoming the main reason immunotherapy fails in HCC
What the researchers found
Co-administered iRGD peptide enhanced anti-PD-L1 therapy in HCC: improved antibody tumor penetration, increased T cell infiltration, overcame immunosuppressive TME, and significantly outperformed anti-PD-L1 alone.
Why it matters
Most liver cancer patients don't respond to immunotherapy because the drug can't penetrate the tumor. A simple peptide co-infusion could change this.
How the study worked
HCC mouse models treated with anti-PD-L1 ± internalizing RGD peptide, with tumor penetration, T cell infiltration, TME analysis, and tumor growth assessment.
What this study cannot tell us
Mouse models. Human HCC is heterogeneous. iRGD manufacturing and dosing in humans not optimized.
How to read the evidence
Comprehensive preclinical with multi-model validation.
When this study was published
Published in 2025.
The bigger picture
Peptide-enhanced tumor penetration could be a general strategy to improve immunotherapy across solid tumors that resist checkpoint inhibitors.
Questions still open
- Would iRGD enhance immunotherapy for other solid tumor types?
- Is the effect dose-dependent?
- Could iRGD be combined with other checkpoint inhibitors (anti-PD-1, anti-CTLA-4)?
Common questions
Why doesn't immunotherapy work for many liver cancers?
How simple is adding the peptide?
Read the original research
Co-administered internalizing RGD peptide boosts anti-PD-L1 therapy in hepatocellular carcinoma.
JHEP reports : innovation in hepatology, 8(3), 101731
Citation
Klug, Jan Henrik; Aliraj, Blerina; Alcober-Boquet, Lucia; Denk, Dominic; Germann, Lena; Meindl-Beinker, Nadja M; De La Torre, Carolina; Waidmann, Oliver; Finkelmeier, Fabian; Zeuzem, Stefan; Brüne, Bernhard; Vogl, Thomas J; Weigert, Andreas; Piiper, Albrecht. (2026). Co-administered internalizing RGD peptide boosts anti-PD-L1 therapy in hepatocellular carcinoma.. JHEP reports : innovation in hepatology, 8(3), 101731. https://doi.org/10.1016/j.jhepr.2026.101731